A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Authors : Murat Çalapkulu, Muhammed Erkam Sencar, Ilknur Öztürk Ünsal, Hayri Bostan, Erman Çakal

Pages : 85-86

Doi:10.46310/tjim.877156

View : 28 | Download : 8

Publication Date : 2021-03-07

Article Type : Other

Abstract :Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.
Keywords : Dapagliflozin, sodium-glucose co-transporter 2 inhibitors, euglycemic ketoacidosis